Neratinib, also known as neratinib maleate, can treat Her2-positive breast cancer and help prolong survival. Neratinib is actually a pan-ErbB receptor tyrosine kinase inhibitor, which is mainly used in the treatment of HER2-positive metastatic breast cancer, especially in patients who have failed 2 or more previous HER2-targeted therapies (third line). The drug ingredient Neratinib Maleate can directly act on the HER2 receptors on the surface of HER2-positive cancer cells, inhibit ErbB1 and ErbB2, prevent cancer cells from continuing to replicate and avoid continued growth of tumors, thus prolonging the survival time of patients. However, patients may have adverse reactions such as diarrhea, nausea, vomiting, abdominal pain during the drug administration, and need to be properly monitored; in addition, pregnant women need to be prohibited from use. The effect of Neratinib on Her2-positive breast cancer is still good, but need to have professional doctor’s guidance.